Mulloy, L L <br/><br/>
Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors.  [electronic resource] 

 -  Transplantation proceedings   
 - 1210-3 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0041-1345 
<br/><br/><label>Standard No.: </label>10.1016/s0041-1345(98)02094-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--therapeutic use<br/>Basiliximab<br/>Cadaver<br/>Cyclosporine--therapeutic use<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Female<br/>Graft Rejection--prevention & control<br/>Graft Survival<br/>Histocompatibility Testing<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Kidney Transplantation--immunology<br/>Living Donors<br/>Male<br/>Middle Aged<br/>Recombinant Fusion Proteins<br/>Retrospective Studies<br/>Survival Analysis<br/>Tissue Donors<br/>United States